IP Library Granted Patent US 11,458,158
Granted Patent B2
US 11,458,158 · App. 16/867,291 · Granted Oct 4, 2022

Amino acid-, peptide- and polypeptide-lipids, isomers, compositions, and uses thereof

Inventors: Yizhou Dong (Dublin, OH); Kevin Thomas Love (Boston, MA); Robert S. Langer (Newton, MA); Daniel Griffith Anderson (Framingham, MA); Delai Chen (Cambridge, MA); Yi Chen (Cambridge, MA); Arturo Jose Vegas (Belmont, MA); Akinleye C. Alabi (Ithaca, NY); Yunlong Zhang (Cambridge, MA)
Assignee: Massachusetts Institute of Technology
A61K31/7105A61K31/711A61K47/22C07C229/12C07C229/22C07C229/24C07C229/26C07C229/36C07C237/08C07C237/12C07C271/22C07C279/14C07C323/58C07D207/16C07D209/20C07D209/24C07D233/64C07D241/08C07D265/32C07D403/06C07D413/06C07D487/04C07D487/06C12N15/87C12N15/88C12Q1/025G01N33/15A61K2121/00Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,458,158
App. No.
16/867,291
Granted
Oct 4, 2022
Kind
B2
Abstract

Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R′, R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , Z, W, Y, and Z are as defined herein.

Claims (49)

1. A composition comprising a polynucleotide, and a compound of Formula (III):

or salt thereof, wherein:

p is 1;

each instance of Q is O;

each instance of R 1 is independently hydrogen, alkyl, or a group of formula (iv);

provided at least one instance of R 1 is a group of formula:

L is alkylene;

R 6 and R 7 are each independently hydrogen, alkyl, a nitrogen protecting group, or a group of the formula (i), (ii), or (iii);

each instance of R 2 is independently hydrogen, alkyl, a nitrogen protecting group, or a group of the formula (i), (ii), or (iii);

Formulae (i), (ii), and (iii) are:

wherein each instance of formula (i) is independently formula (i-a) or formula (i-b):

each instance of R′ is independently hydrogen or alkyl;

X is O, S, or NR X , wherein R X is hydrogen, or a nitrogen protecting group;

Y is O;

R P is hydrogen, or alkyl, an oxygen protecting group; and

R L is C 6-50 alkyl,

provided that at least one instance of R 2 , R 6 , or R 7 is a group of the formula (i), (ii), or (iii);

wherein each alkyl and alkylene is independently unsubstituted or substituted at one or more positions with a group selected from halogen, —CN, —NO 2 , —OH, —OR aa , —N(R bb ) 2 , —N(R bb ) 3 + X − , —N(OR cc )R bb , —SH, —SR aa , —C(═O)R aa , —CO 2 H, —CHO, —C(OR cc ) 2 , —CO 2 R aa , —OC(═O)R aa , —OCO 2 R aa , —C(═O)N(R bb ) 2 , —OC(═O)N(R bb ) 2 , —NR bb C(═O)R aa , —NR bb CO 2 R aa , —NR bb C(═O)N(R bb ) 2 , —C(═NR bb )R aa , —C(═NR bb )OR aa , —OC(═NR bb )R aa , —OC(═NR bb )OR aa , —C(═NR bb )N(R bb ) 2 , —OC(═NR bb )N(R bb ) 2 , —NR bb C(═NR bb )N(R bb ) 2 , C 3-14 carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, and 5-14 membered heteroaryl, wherein each alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 groups selected from halogen, —OH, —OR ee , and C 1-50 alkyl;

or two geminal hydrogens on a carbon atom are replaced with the group ═O;

each instance of R aa is, independently, selected from C 1-50 alkyl;

each instance of R bb is, independently, selected from hydrogen and C 1-50 alkyl;

each instance of R bb is, independently, selected from C 1-50 alkyl and C 3-10 carbocyclyl; wherein X − is a counterion.

2. The composition of claim 1 , wherein X is O.

3. The composition of claim 1 , wherein each instance of R 1 is a group of formula (iv).

4. The composition of claim 1 , wherein each instance of R 2 is independently hydrogen or a group of the formula (i), (ii), or (iii).

5. The composition of claim 1 , wherein the group of formula (iv) is of formula:

wherein q is an integer between 1 and 50, inclusive.

6. The composition of claim 1 , wherein the compound is selected from the group consisting of:

and salts thereof,

wherein:

R 1 is selected from the group consisting of —H, —CH 3 , —CH(CH 3 ) 2 , —CH(CH 3 )(CH 2 CH 3 ), —CH 2 CH(CH 3 ) 2 ,

provided at least one R 1 is a group of formula:

7. The composition of claim 6 , wherein at least one instance of R 6 or R 7 is a group of the formula (i), (ii), or (iii).

8. The composition of claim 1 , wherein the compound is selected from the group consisting of:

and salts thereof.

9. The composition of claim 1 , wherein the compound is selected from the group consisting of:

and salts thereof.

10. The composition of claim 9 , wherein the compound is:

or salt thereof.

11. The composition of claim 1 , wherein the composition is a pharmaceutical composition.

12. The composition of claim 1 , wherein the composition further comprises cholesterol.

13. The composition of claim 1 , wherein the composition further comprises a PEGylated lipid.

14. The composition of claim 1 , wherein the composition further comprises a phospholipid.

15. The composition of claim 1 , wherein the polynucleotide is RNA.

16. The composition of claim 15 , wherein the RNA is RNAi, dsRNA, siRNA, shRNA, miRNA, or antisense RNA.

17. The composition of claim 15 , wherein the RNA is able to interfere with the expression of a specific gene in the biological cell.

18. The composition of claim 1 , wherein the polynucleotide is DNA.

19. The composition of claim 1 , wherein the polynucleotide encodes a protein or peptide.

20. The composition of claim 1 , wherein the composition is in the form of a particle.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2020
From: DONG, YIZHOU; LOVE, KEVIN THOMAS; LANGER, ROBERT S.; ANDERSON, DANIEL GRIFFITH; CHEN, DELAI; CHEN, YI; VEGAS, ARTURO JOSE; ALABI, AKINLEYE; ZHANG, YUNLONG
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 053395/0536 →
Continuity (5)
Continuation 16126897 · Sep 10, 2018
Division 15340082 · Nov 1, 2016
Division 13662002 · Oct 26, 2012
Provisional Application 61552423 · Oct 27, 2011
Related Publication 20200330501A1 · Oct 22, 2020
Cited By (2)
US 12,390,528 US 12,648,959